

ΚΥΠΡΙΑΚΟ ΓΡΑΦΕΙΟ ΔΙΠΛΩΜΑΤΩΝ ΕΥΡΕΣΙΤΕΧΝΙΑΣ
THE PATENT OFFICE OF CYPRUS

ΑΡΙΘΜΟΣ ΔΗΜΟΣΙΕΥΣΗΣ **CY1988**
PUBLICATION NUMBER

ΑΡΙΘΜΟΣ ΔΗΜΟΣΙΕΥΣΗΣ
ΓΡΑΦΕΙΟΥ ΔΙΠΛΩΜΑΤΩΝ ΕΥΡΕΣΙΤΕΧΝΙΑΣ
ΗΝΩΜΕΝΟΥ ΒΑΣΙΛΕΙΟΥ
UK PATENT OFFICE
PUBLICATION NUMBER GB2248185

Το έγγραφο που παρουσιάζεται πιο κάτω καταχωρήθηκε στο «Γραφείο Διπλωμάτων Ευρεσιτεχνίας» στην Αγγλία σύμφωνα με το Νόμο Κεφ. 266 πριν την 1η Απριλίου 1998. Δημοσίευση έγινε μετέπειτα από το Γραφείο Διπλωμάτων Ευρεσιτεχνίας του Ηνωμένου Βασιλείου μόνο στην Αγγλική γλώσσα.

The document provided hereafter was filed at "The Patent Office" in England under the law CAP.266 before the 1st of April 1998. It was published afterwards by the UK patent office only in English.

(12) UK Patent Application (19) GB (11) 2 248 185 (13) A

(43) Date of A publication 01.04.1992

(21) Application No 9119284.9

(22) Date of filing 10.09.1991

(30) Priority data
(31) 9019875 (32) 11.09.1990 (33) GB

(71) Applicant
Glaxo Group Limited

(Incorporated in the United Kingdom)

Glaxo House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, United Kingdom

(72) Inventors
Norman Richard Smith
Colin Roy Heppenstall
Stephen John Douglas

(74) Agent and/or Address for Service
Elkington and Fife
Prospect House, 8 Pembroke Road, Sevenoaks, Kent, TN13 1XR, United Kingdom

(51) INT CL[5]
A61K 31/29

(52) UK CL (Edition K)
A5B BKC B180 B28Y B285 B44Y B446 B45Y B451 B452 B453 B54Y B540 B56Y B565
U1S S1318 S1330

(56) Documents cited
GB 2220937 A EP 0367484 A1

(58) Field of search
UK CL (Edition K) A5B BKC BLM
INT CL[5] A61K
Online databases: WPI, CLAIMS, CHABS, MEDLINE

(54) Ranitidine formulations

(57) Oral compositions in solid unit dosage form comprise a salt formed between ranitidine and a complex of bismuth with a carboxylic acid selected from tartaric acid and citric acid together with an alkaline salt. The formulation is e.g. in tablet form and comprises ranitidine bismuth citrate and sodium carbonate and has improved disintegration and/or dissolution. Alkaline salts may be Na_2CO_3, $NaHCO_3$, $(NH_4)_2\ CO_3$, dipotassium phosphate etc.

GB 2 248 185 A

PHARMACEUTICAL COMPOSITIONS CONTAINING FURAN DERIVATIVES

The present invention relates to improvements in the formulation of derivatives of the H_2-receptor antagonist ranitidine, particularly for oral administration. More especially the invention is concerned with pharmaceutical compositions in which the active ingredient is a salt of ranitidine and a complex of bismuth with a carboxylic acid.

Published UK Patent Specification No. 2220937A describes and claims salts formed between ranitidine and a complex of bismuth with a carboxylic acid, particularly tartaric acid and, more especially, citric acid. Such salts possess the H_2-antagonist antisecretory properties associated with ranitidine, together with antibacterial activity against Helicobacter pylori (formerly Campylobacter pylori). In addition, such salts possess cytoprotective properties, and display activity against the human gastric pepsins, with preferential inhibition of pepsin 1, a pepsin isozyme associated with peptic ulcer.

The salts disclosed in UK Patent Specification No. 2220937A thus possess a particularly advantageous combination of properties for the treatment of gastrointestinal disorders, especially peptic ulcer disease and other gastroduodenal conditions, for example gastritis and non-ulcer dyspepsia.

UK Patent Specification No. 2220937A also discloses pharmaceutical compositions containing salts formed between ranitidine and a complex of bismuth with a carboxylic acid. Such compositions are primarily intended for oral administration, and may take the form of for example tablets, capsules, solutions, syrups, suspensions or dry products for constitution with water or other suitable vehicle before use.

One of the important properties associated with pharmaceutical compositions in solid form for oral administration is that, once swallowed by the patient, they should disintegrate and/or dissolve in order to release the active ingredient. It has now been found that the rate of disintegration and/or dissolution of such

compositions, in particular tablets, containing a salt of the type described in UK Patent Specification No. 2220937A as the active ingredient, may be significantly improved, particularly under acid conditions, by incorporating an alkaline salt into the formulation. This in turn serves to increase the extent to which the active ingredient is released from the composition.

Thus the present invention provides a pharmaceutical composition in solid unit dosage form for oral administration, comprising a salt formed between ranitidine and a complex of bismuth with a carboxylic acid selected from tartaric acid or citric acid, and an alkaline salt.

Compositions containing solvates, including hydrates, of the ranitidine salts are also included within the scope of the invention.

The salt of ranitidine may be for example N-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro-1,1-ethenediamine 2-hydroxy-1,2,3-propanetricarboxylate bismuth (3^+) complex, also known as ranitidine bismuth citrate; or N-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro-1, 1-ethenediamine [R-(R*R*)]-2,3-dihydroxybutanedioate bismuth (3^+) complex, also known as ranitidine bismuth tartrate. Such salts may be formed by reacting ranitidine with an appropriate bismuth carboxylic acid complex, e.g. bismuth citrate or bismuth tartrate.

Compositions containing ranitidine bismuth citrate as the active ingredient are particularly preferred.

The alkaline salt may be for example a carbonate, bicarbonate, citrate, phosphate, acetate, or chloride salt. The use of an alkali metal (e.g. sodium or potassium) or alkaline earth metal (e.g. magnesium or calcium) carbonate or bicarbonate, or mixtures thereof is preferred. Sodium bicarbonate and/or sodium carbonate is particularly preferred, more especially sodium carbonate, which may conveniently be used in its anhydrous form. Examples of other suitable alkaline salts that may be used include ammonium citrate, ammonium carbonate, ammonium phosphate, ammonium chloride, sodium acetate, sodium citrate, sodium phosphate, potassium acetate, potasssium citrate and dipotassium phosphate.

The amount of ranitidine bismuth carboxylate in the composition according to the invention may be for example 150mg to 1.5g, preferably 200 to 800mg.

The alkaline salt may constitute for example 2% to 20% of the composition on a weight-to-weight (w/w) basis, preferably 2% to 8%.

The ranitidine bismuth carboxylate content of the composition may be for example 20% to 95%, preferably 50% to 95%, more particularly 80% to 95%, on a w/w basis.

A preferred composition comprises ranitidine bismuth citrate and sodium carbonate.

The compositions according to the invention are intended for use in human or veterinary medicine.

The composition may be administered, for example, one to four times daily, preferably once or twice. The dosage will however depend on the nature and severity of the condition being treated, and it will also be appreciated that it may be necessary to make routine variations to the dosage depending on the age and weight of the patient.

The composition may take the form of for example tablets (including chewable tablets), capsules (of either the hard or soft type), powders or granules. Tablets are preferred.

The composition according to the invention may be formulated using additional physiologically acceptable carriers or excipients as appropriate. Such additional carriers or excipients may be for example binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. starch or sodium starch glycollate); or wetting agents (e.g. sodium lauryl sulphate). Tablets may be coated by methods well known in the art. The preparations may also contain flavouring, colouring and/or sweetening agents as appropriate.

Compositions according to the invention may be prepared according to conventional techniques well known in the pharmaceutical industry for the manufacture of solid dosage forms for oral administration. Thus the ranitidine

bismuth carboxylate and alkaline salt may, for example, be blended with suitable excipients and, if desired, granulated. Tablets may be prepared, for example, by compression of the blend or granulate, using a lubricant as an aid to tabletting.

The following Examples illustrate tablets and capsules according to the invention in which the active ingredient is in particular ranitidine bismuth citrate.

Tablets may be film coated with suitable film forming materials, such as hydroxypropyl methylcellulose, using standard techniques.

Example 1	mg/tablet		
Active ingredient	200.0	400.0	800.0
Anhydrous sodium carbonate USNF	19.0	25.0	46.0
Microcrystalline cellulose Ph. Eur.	149.6	60.0	46.0
Polyvinylpyrrolidone	7.6	10.0	18.4
Magnesium stearate Ph. Eur.	3.8	5.0	9.2
Compression weight	380.0	500.0	919.6

The active ingredient, sodium carbonate and microcrystalline cellulose were blended together, granulated using a solution of the polyvinylpyrrolidone in isopropyl alcohol, and dried. The granule was blended with magnesium stearate and compressed into tablets using suitable punches.

Example 2	mg/tablet	
Active ingredient	400.0	400.0
Sodium bicarbonate USNF	85.0	21.7
Polyvinylpyrrolidone	10.0	8.7
Magnesium stearate Ph. Eur.	5.0	4.4
Compression weight	500.0	434.8

The active ingredient and sodium bicarbonate were blended together, granulated using a solution of the polyvinylpyrrolidone in isopropyl alcohol, and dried. The granule was blended with magnesium stearate and compressed into tablets using suitable punches.

Example 3	mg/tablets
Active ingredient	400.0
Anhydrous sodium carbonate USNF	2.5
Sodium bicarbonate USNF	22.5
Microcrystalline cellulose Ph. Eur.	60.0
Polyvinylpyrrolidone	10.0
Magnesium stearate Ph. Eur.	5.0
Compression weight	500.0

Tablets were prepared according to the method described in Example 1, using the sodium carbonate and sodium bicarbonate in place of sodium carbonate alone.

Example 4	mg/tablets
Active ingredient	600.0
Anhydrous sodium carbonate USNF	36.0
Lactose	60.0
Polyvinylpyrrolidone	15.0
Magnesium stearate	8.0
Compression weight	719.0

The active ingredient, sodium carbonate and lactose are blended together, granulated using a solution of the polyvinylpyrrolidone in ethyl alcohol, and dried. The granule is blended with magnesium stearate and compressed into tablets using suitable punches.

Example 5	mg/tablets
Active ingredient	600.0
Sodium bicarbonate USNF	36.0
Lactose	60.0
Polyvinylpyrrolidone	15.0
Magnesium stearate	8.0
Compression weight	719.0

The active ingredient, sodium bicarbonate and lactose are blended together, granulated using a solution of the polyvinylpyrrolidone in isopropyl alcohol, and dried. The granule is blended with magnesium stearate and compressed into tablets using suitable punches.

Example 6	mg/capsule
Active ingredient	400.0
Anhydrous sodium carbonate USNF	2.5
Sodium bicarbonate USNF	22.5
Microcrystalline cellulose Ph. Eur.	57.5
Polyvinylpyrrolidone	10.0
Magnesium stearate	5.0
Silicon dioxide	2.5
Fill weight	500.0

The active ingredient, sodium carbonate, sodium bicarbonate and microcrystalline cellulose are blended together, granulated using a solution of the polyvinylpyrrolidone in isopropyl alcohol, and dried. The granule is blended with magnesium stearate and silcon dioxide, and filled into hard gelatin capsules of a suitable size using conventional capsule filling machinery.

Example 7	mg/capsule
Active ingredient	400.0
Anhydrous sodium carbonate USNF	25.0
Microcrystalline cellulose	72.5
Silicon dioxide	2.5
Fill weight	500.0

The microcrystalline cellulose and silicon dioxide are blended to form a pre-blend. This in turn is blended with the active ingredient and sodium carbonate. The resulting blend is filled into hard gelatin capsules of a suitable size using conventional capsule filling machinery.

Example 8	mg/tablet
Active ingredient	800.0
Anhydrous Sodium Carbonate USNF	46.0
Microcrystalline Cellulose Ph.Eur	46.0
Polyvinylpyrrolidone	18.4
Magnesium Stearate	9.2
	918.6

The active ingredient, sodium carbonate and microcystalline cellulose were blended together, granulated with a solution of the polyvinylpyrrolidone in a mixture of isopropyl alcohol and water (90:10) and dried. The granule was blended with magnesium stearate and compressed into tablets using suitable punches.

Example 9	mg/tablet
Active ingredient	750.0
Sodium Carbonate	45.0
Lactose	78.0
Polyvinylpyrrolidone	18.0
Magnesium Stearate	9.0
	900.0

The active ingredient, sodium carbonate and lactose are blended together, granulated using a solution of polyvinylpyrrolidone in isopropyl alcohol and dried. The granule is blended with magnesium stearate and compressed into tablets using suitable punches.

CLAIMS:

1. A pharmaceutical composition in solid unit dosage form adapted for oral administration, comprising a salt formed between ranitidine and a complex of bismuth with a carboxylic acid selected from tartaric acid and citric acid together with an alkaline salt.

2. A composition as claimed in claim 1, containing from 200 to 800mg of ranitidine bismuth carboxylate per unit dose.

3. A composition as claimed in claim 1 or 2, containing from 2 to 20% w/w of the alkaline salt.

4. A composition as claimed in claim 1 or 2, containing from 2 to 8% w/w of the alkaline salt.

5. A composition as claimed in any of claims 1 to 4, containing from 50 to 95% w/w of ranitidine bismuth carboxylate.

6. A composition as claimed in any of claims 1 to 5, wherein the salt of ranitidine is:
N-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro-1,1-ethenediamine 2-hydroxy-1,2,3-propanetricarboxylate bismuth (3^+) complex; or
N-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro-1,1-ethenediamine [R-(R^*R^*)]-2,3-dihydroxybutanedioate bismuth (3^+) complex.

7. A composition as claimed in any of claims 1 to 6 wherein the alkaline salt is a carbonate, bicarbonate, citrate, phosphate, acetate or chloride salt.

8. A composition as claimed in any of claims 1 to 6, wherein the alkaline salt is an alkali metal or an alkaline earth metal carbonate or bicarbonate or a mixture thereof.

9. A composition as claimed in any of claims 1 to 6, wherein the alkaline salt is sodium carbonate and/or sodium bicarbonate.

10. A composition as claimed in any of claims 1 to 5, wherein the ranitidine bismuth carboxylate is N-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-

methyl-2-nitro-1,1-ethenediamine 2-hydroxy-1,2,3-propanetricarboxylate bismuth (3^+) complex and the alkaline salt is sodium carbonate.

11. A composition as claimed in any of claims 1 to 10 in the form of tablets.

12. A composition as claimed in any of claims 1 to 11, also containing one or more physiologically acceptable carriers or excipients.

13. A process for the preparation of a pharmaceutical composition as claimed in any of claims 1 to 12, which comprises processing the ranitidine bismuth carboxylate and the alkaline salt into a solid unit dosage form suitable for oral administration.

Patents Act 1977
Examiner's report to the Comptroller under Section 17 (The Search Report)

Application number
9119284.9

Relevant Technical fields

(i) UK Cl (Edition K) A5B(BKC,BLM)

(ii) Int Cl (Edition 5) A61K

Search Examiner
M R WENDT

Databases (see over)

(i) UK Patent Office

(ii) ONLINE DATABASES: WPI, CLAIMS, CHABS, MEDLINE

Date of Search
19 NOVEMBER 1991

Documents considered relevant following a search in respect of claims 1-13

Category (see over)	Identity of document and relevant passages	Relevant to claim(s)
A	GB A 2220937 (GLAXO) see eg Claims 1,4, 10-12. Page 6 line 11 etc	1
A	EP A1 0367484 (GLAXO) see eg see Claim 1. Page 4 line 8 etc	1

Category	Identity of document and relevant passages	Relevant to claim(s)

Categories of documents

X: Document indicating lack of novelty or of inventive step.

Y: Document indicating lack of inventive step if combined with one or more other documents of the same category.

A: Document indicating technological background and/or state of the art.

P: Document published on or after the declared priority date but before the filing date of the present application.

E: Patent document published on or after, but with priority date earlier than, the filing date of the present application.

&: Member of the same patent family, corresponding document.

Databases: The UK Patent Office database comprises classified collections of GB, EP, WO and US patent specifications as outlined periodically in the Official Journal (Patents). The on-line databases considered for search are also listed periodically in the Official Journal (Patents).

Published 1992 at The Patent Office, Concept House, Cardiff Road, Newport, Gwent NP9 1RH. Further copies may be obtained from Sales Branch, Unit 6, Nine Mile Point, Cwmfelinfach, Cross Keys, Newport, NP1 7HZ. Printed by Multiplex techniques ltd, St Mary Cray, Kent.